Brief: Universal Biosensors Says Extends Clinical Development Trials For TN Antigen Cancer Biosensor
20/09/2021 02:52
Sept 20 (Reuters) - Universal Biosensors Inc UBI.AX :
* EXTENDS CLINICAL DEVELOPMENT TRIALS FOR TN ANTIGEN CANCER
BIOSENSOR
Source text for Eikon: ID:nASX8cX5zf
Further company coverage: UBI.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Universal Biosensors
See all newsBrief: Universal Biosensors Seeks Trading Halt Pending Announcement On Financial Position & Funding
Brief: Universal Biosensors Signs Non-Binding Term Sheet For A$8.5M Funding
Brief: Universal Biosensors Seeks Trading Halt
Brief: Universal Biosensors Inc Posts Qtrly Total Revenue A$1.6 Million
Brief: Universal Biosensors Says John Sharman Steps Down As Managing Director And CEO